Wells Fargo Names Six SMID-Cap Biotech Picks to Watch in 2026
Wells Fargo’s 2026 biotech outlook narrows its high-conviction SMID-cap ideas to six companies it expects to outperform based on near-term clinical readouts, regulatory milestones, and commercial rollouts. The bank’s coverage spans 22 names, but Ionis, Beam, Taysha, Sarepta, Spyre and RAPT stand out for their pipeline depth, upcoming data, and fina…